Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Incorporated reports news around its precision oncology pipeline, including clinical and preclinical programs aimed at genetically and epigenetically defined cancer targets. Recurring updates cover PRT12396, a mutant-selective JAK2V617F inhibitor being developed for certain myeloproliferative neoplasms, and PRT13722, an orally bioavailable selective KAT6A degrader being developed in breast cancer.
Company announcements also address FDA and IND-related developments, preclinical data presentations at oncology and hematology meetings, financial results, investor presentations, executive appointments, and capital-structure activity tied to its Nasdaq-listed common stock.
Prelude Therapeutics (NASDAQ:PRLD) announced an exclusive option agreement with Incyte (NASDAQ:INCY) for Prelude’s mutant selective JAK2V617F JH2 inhibitor program for myeloproliferative neoplasms (MPNs).
Prelude will receive $60 million in capital at close ($35M upfront plus $25M strategic equity via 6.25M shares at $4.00), an option purchase price of $100 million, and up to $775 million in milestones plus royalties, for combined potential cash of $910 million excluding royalties. Prelude retains program rights if Incyte declines the option. Program data accepted for an oral ASH presentation Dec 6-9, 2025.
Prelude Therapeutics (Nasdaq: PRLD) announced publication of two abstracts accepted for oral presentation at the ASH 67th Annual Meeting, December 6-9, 2025 in Orlando.
The abstracts report preclinical data for two discovery programs: orally bioavailable JAK2V617F JH2 mutant-selective inhibitors showing mutant-specific inhibition, normalization of blood counts and spleen size in JAK2VF mouse models and selective reduction of JAK2VF progenitors; and mCALR-targeted DACs delivering a CDK9 degrader that selectively eliminates CALR-mutant MPN progenitors while sparing healthy CD34+ cells.
Prelude Therapeutics (Nasdaq: PRLD) announced that Katina Dorton, J.D., MBA was appointed to its Board of Directors effective October 17, 2025.
Ms. Dorton brings >30 years of healthcare and life‑sciences experience, including senior finance roles, investment banking, service as CFO at NodThera, and having raised $82 million in crossover funding while at Repare Therapeutics. She will succeed Mardi C. Dier, who is resigning from the board effective October 17, 2025, and Ms. Dorton will assume the role of Audit Committee chair.
Prelude Therapeutics (Nasdaq: PRLD) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company's oral SMARCA2 degrader PRT7732 is currently enrolling its seventh dosing cohort at 125mg, with preliminary data expected by year-end 2025. Prelude has completed Phase 1 study of PRT3789, its IV SMARCA2 degrader, but decided to pause its development to focus resources on PRT7732.
The company reported $77.3 million in cash and equivalents as of June 30, 2025, providing runway into Q2 2026. Q2 net loss was $31.2 million ($0.41 per share), improved from $34.7 million ($0.46 per share) in Q2 2024. The company remains on track to file an IND for its oral KAT6A degrader program in H1 2026.
Prelude Therapeutics (Nasdaq: PRLD) announced new preclinical data presentations at the 2025 AACR Annual Meeting for two key programs. The first presentation focuses on PRT3789, their first-in-class selective SMARCA2 degrader currently in Phase 1 and 2 clinical trials for advanced solid tumors with SMARCA4 loss.
The second presentation highlights their KAT6A degrader program, showing promising preclinical results in breast cancer and other solid tumors. Their selective KAT6A degraders demonstrated:
- Deep anti-cancer responses in KAT6A-amplified tumors
- Complete tumor regressions in breast and lung cancer xenografts
- Reduced hematologic toxicity compared to KAT6A/B inhibitors
- Effectiveness against endocrine therapy and CDK4/6i-resistant cells
Prelude Therapeutics (Nasdaq: PRLD) reported its full year 2024 financial results and clinical program updates. The company's lead drug PRT3789, a first-in-class SMARCA2 degrader, demonstrated clinical proof-of-concept with anti-tumor activity in SMARCA4-deficient cancers. Of 32 evaluable patients, 5 showed confirmed partial responses.
Financial highlights include:
- Cash position of $133.6 million as of December 31, 2024, funding operations into Q2 2026
- R&D expenses increased to $118.0 million from $103.4 million in 2023
- Net loss of $127.2 million ($1.68 per share) compared to $121.8 million ($2.02 per share) in 2023
Key upcoming milestones include additional results from PRT3789 monotherapy and docetaxel combination studies, plus interim data from oral SMARCA2 degrader PRT7732 in H2 2025. The company also plans to seek a partner for its CDK9 inhibitor PRT2527 to focus on SMARCA2 degrader development.
Prelude Therapeutics (Nasdaq: PRLD), a clinical-stage precision oncology company, has announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, FL on March 11, 2025.
Key executives participating in a fireside chat at 12:30 p.m. ET include:
- Kris Vaddi, Ph.D., Chief Executive Officer
- Jane Huang, M.D., President and Chief Medical Officer
- Bryant Lim, Chief Financial Officer
The event will be accessible via live webcast on the Company's website under Events and Presentations, with the recording remaining available for 90 days. Prelude Therapeutics specializes in developing innovative medicines for cancer patients, focusing on:
- First-in-class SMARCA2 degraders (IV and oral)
- CDK9 inhibitor development
- Precision ADCs (Degrader Antibody Conjugates) through partnerships